NCT01707290View on ClinicalTrials.gov

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

PHASE3CompletedINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Cystic Fibrosis

Interventions

DRUG

Ivacaftor

150 mg tablet, oral use, every 12 hours (q12h)

Trial Locations (38)

Unknown

Birmingham

Palo Alto

Denver

Hartford

Tampa

Atlanta

Chicago

Iowa City

Lexington

Baltimore

Boston

Ann Arbor

Detroit

Grand Rapids

Minneapolis

St Louis

Omaha

New York

Syracuse

Valhalla

Chapel Hill

Philadelphia

Pittsburgh

Charleston

Nashville

Dallas

Fort Worth

Houston

Salt Lake City

Richmond

Seattle

Morgantown

Madison

Leuven

Montpellier

Paris

Belfast

Edinburgh

All Listed Sponsors

collaborator

Cystic Fibrosis Foundation

OTHER

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01707290 - Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation | Biotech Hunter | Biotech Hunter